Please assess the completion status of the following clinical trial:

Trial Title: Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed hematopathology diagnosis of AML receiving marrow suppressive treatment~* Total WBC recovery of 500 mm3 prior to IL-2 treatment~* Platelet count of at least 20,000 mm3 prior to starting IL-2 treatment~* Active infection controlled prior to starting IL-2 treatment~* Stable systolic blood pressure \> 90mm Hg prior to starting IL-2 treatment~* O2 saturation \>90% prior to starting treatment~* Stable cardiopulmonary status prior to starting IL-2 treatment~* Serum creatinine \< or equal to 2.0 mg/dl~* Total bilirubin and AST \<3x upper limits normal~Exclusion Criteria:~* Acute Promyelocytic Leukemia~* Active thrombocytopenic bleeding~* Cardiac ejection fraction below 45%~* Pregnancy and/or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- interleukin-2 (Type: EXPERIMENTAL): interleukin-2 therapy during lymphocyte recovery

Based on this trial design, predict the completion outcome and termination type (if applicable).